Stockscreener 앱 받기
8.20
3.87%
-0.33
시간 외 거래:
8.25
0.05
+0.61%
전일 마감가:
$8.53
열려 있는:
$8.67
하루 거래량:
112.15K
Relative Volume:
1.16
시가총액:
$210.04M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-5.8156
EPS:
-1.41
순현금흐름:
$-15.54M
1주 성능:
+11.11%
1개월 성능:
+22.21%
6개월 성능:
+8.75%
1년 성능:
+24.05%
1일 변동 폭
$8.0001
$8.70
1주일 범위
$7.22
$8.70
52주 변동 폭
$5.34
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.20 | 218.50M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Maxim Group | Buy |
| 2025-03-17 | 개시 | Laidlaw | Buy |
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Will Nuvectis Pharma Inc. stock benefit from commodity prices2026 world cup usa national team group stage young talents transition play group prediction preview - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b - GlobeNewswire
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
Will Nuvectis Pharma Inc. stock attract more institutional investors2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Will Nuvectis Pharma Inc. stock split attract more investors2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Published on: 2025-11-30 11:27:46 - BỘ NỘI VỤ
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - marketscreener.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader - GlobeNewswire
Trading the Move, Not the Narrative: (NVCT) Edition - news.stocktradersdaily.com
How Nuvectis Pharma Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nuvectis Pharma Inc. stock trendline breakdownPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
How currency fluctuations impact Nuvectis Pharma Inc. stockEarnings Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):